Laboratory/Clinical Translational Research
The Clinical Significance of Tenascin-C Splice Variant Expression in ChondrosarcomaGhert M.A.a · Jung S.T.a · Qi W-n.a · Harrelson J.M.a · Erickson H.P.b · Block J.A.c · Scully S.P.d
aDivision of Orthopedic Surgery, and bDepartment of Cell Biology, Duke University Medical Center, Durham, N.C., cDepartment of Rheumatology, Rush-Presbyterian St. Luke’s Medical Center, Chicago, Ill., and dDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minn., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objectives: Tenascin-C (TNC) is an oligomeric glycoprotein of the extracellular matrix that is prominently expressed in malignant tumors. The purpose of this study was: (1) to determine the in vitro TNC splicing pattern in cultured human chondrocytes and chondrosarcoma cells, (2) to determine the in vivo TNC splicing pattern in clinical chondrosarcoma specimens, and (3) to perform survival analysis based on the TNC splicing pattern of the tumor specimens. Methods: Human articular chondrocytes and chondrosarcoma cells (cell line JJ012) were grown in a three-dimensional alginate bead system and harvested at two time points. Semiquantitative reverse transcription polymerase chain reaction (RT-PCR) was used to determine the in vitro TNC splicing pattern for the two cell types. Clinical chondrosarcoma specimens were obtained intra-operatively and underwent RT-PCR to determine the in vivo TNC splicing pattern. Specific immunohistochemical staining for the large TNC splice variant was performed on the clinical specimens. Survival analysis was used to determine the association between the specific TNC splicing pattern and survival. Results: The in vitro mRNA expression pattern of TNC in normal human articular chondrocytes was characterized by a high ratio of the small to the large splice variant (TNCsmall:TNClarge), whereas the in vitro mRNA expression pattern for cultured chondrosarcoma cells was characterized by a low TNCsmall:TNClarge ratio. Clinical chondrosarcoma specimens with a lower TNCsmall:TNClarge ratio showed a trend towards decreased survival. The TNC splicing pattern of these specimens was verified through specific immunohistochemical staining for the large TNC isoform. Conclusions: The specific TNC splicing pattern may have clinical significance in chondrosarcoma. TNC expression may therefore play a future role in objecitve tumor grading and novel therapeutic approaches to this malignancy.
© 2001 S. Karger AG, Basel
- Gluhak J, Mais A, Mina M: Tenascin-C is associated with early stages of chondrogenesis by chick mandibular ectomesenchymal cells in vivo and in vitro. Dev Dyn 1996;205:24–40.
Mackie EJ, Ramsey S: Expression of tenascin in joint-associated tissues during development and postnatal growth. J Anat 1996;188(Pt 1):157–165.
- Mackie EJ, Murphy LI: The role of tenascin-C and related glycoproteins in early chondrogenesis. Microsc Res Tech 1998;43:102–110.
- Dalkowski A, Schuppan D, Orfanos CE, Zouboulis CC: Increased expression of tenascin C by keloids in vivo and in vitro. Br J Dermatol 1999;141:50–56.
- Hakkinen L, et al: Immunolocalization of tenascin-D, alpha9 integrin subunit, and alphavbeta6 integrin during wound healing in human oral mucosa. J Histochem Cytochem 2000;48:985–998.
- Jones FS, Jones PL: The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235–259.
- Latijnhouwers MA, et al: Tenascin expression during wound healing in human skin. J Pathol 1996;178:30–35.
- Gassler N, Rastar F, Hentz MW: Angiogenesis and expression of tenascin after transmural laser revascularization. Histol Histopathol 1999;14:81–87.
- Jallo GI, et al: Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery 1997;41:1052–1059.
- Klein-Soyer C, et al: Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts. Biol Cell 1997;89:295–307.
- Kostianovsky M, et al: Tenascin-C expression in ultrastructurally defined angiongenic and vasculogenic lesions. Ultrastruct Pathol 1997;21:537–544.
Nicolo M, et al: Detection of tenascin-C in surgically excised choroidal neovascular membranes. Graefes Arch Clin Exp Opthalmol 2000;238:107–111.
- Ribatti D, et al: Expression of tenascin is related to angiogenesis in pre-eclampsia. Eur J Clin Invest 1998;28:373–378.
- Kalembey I, et al: Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: An in situ hybridization study. Int J Dev Biol 1997;41:569–573.
- Kurpad SN, et al: Tumor antigens in astrocytic gliomas. Glia 1995;15:244–256.
- Riedl S, et al: Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa. Anticancer Res 1997;17:3165–3166.
- Vacca A, et al: Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-Hodgkin’s lymphomas. Leuk Lymphoma 1996;22:473–481.
- Wilson KE, et al: Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer 1999;80:685–692.
Shrestha P, et al: Tenascin: Growth and adhesion modulation-extracellular matrix degrading function: An in vitro study. Eur J Cancer B Oral Oncol 1996;32B:106–113.
- Jahkola T, et al: Tenascin-C expression in invasion border of early breast cancer: A predictor of local and distant recurrence. Br J Cancer 1998;78:1507–1513.
- Jahkola T, et al: Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996;69:445–447.
- Jahkola T, et al: Expression of tenascin-C in intraductal carcinoma of human breast: Relationship to invasion. Eur J Cancer 1998;34:1687–1692.
- Iskaros BF, et al: Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J Surg Oncol 1998;68:107–112.
- Ishihara A, et al: Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995;1:1035–1041.
- Melis M, et al: Tenascin expression in elastotic cuffs of invasive ductal carcinoma of the breast. Pathol Res Pract 1997;193:479–484.
- Savarese JJ, Erickson H, Scully SP: Articular chondrocyte tenascin-C production and assembly into de novo extracellular matrix. J Orthop Res 1996;14:273–281.
- Erickson HP, Inglesias JL: A six-armed oligomer isolated from cell surface fibronectin preparations. Nature 1984;311:267–269.
- Erickson HP, Taylor HC: Hexabrachion proteins in embryonic chicken tissues and human tumors. J Cell Biol 1987;105:1387–1394.
- Ljubimiv AV, et al: Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 1998;39:1135–1142.
- Springfield DS, Gebhardt MC, McGuire MH: Chondrosarcoma: A review. Instr Course Lect 1996;45:417–424.
- Ozaki T, et al: Chondrosarcoma of the pelvis. Clin Orthop 1997;337:226–239.
- Kuettner KE, Pauli BU, Gall G, Memoli VA, Schenk RK: Synthesis of cartilage matrix by mammalian chondrocytes in vitro. Isolation, culture characteristics, and morphology. J Cell Biol 1982;93:743–750.
- Guo JF, Jourdian GW, MacCallum DK: Culture and growth characteristics of chondrocytes encapsulated in alginate beads. Connect Tissue Res 1989;19:277–297.
Rizzo M, Ghert MA, Harrelson JM, Scully SP: Chondrosarcoma of bone: Review of one-hundred and eight cases and analysis for predictors of outcome. Clin Orthop, in press.
Berend KR, Toth AP, Harrelson JM, Laxfield LJ, Hey LA, Scully SP: Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis and survival in human chondrosarcoma. J Bone Joint Surg 1998;80-A:11–17.
- Tanaka M, et al: Clinical significance of tenascin-C expression in osteosarcoma: Tenascin-C promotes distant metastases of osteosarcoma. Int J Mol Med 2000;5:505–510.
- Sheth DS, et al: Chondrosarcoma of the pelvis – Prognostic factors for 67 patients treated with definitive surgery. Cancer 1996;78:745–750.
Alho A, Connor JF, Mankin HJ, Schiller AL, Campbell CJ: Assessment of malignancy of cartilage tumors using flow cytometry. A preliminary report. J Bone Joint Surg 1983;65-A:779–785.
Alho A, Skjeidal S, Melvik JE, Petterson EO, Larsen TE: The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumors. Anticancer Res 1993;12:2383–2387.
- Kreicbergs A, Boquist L, Borgssen B, Larson S: Prognostic factors in chondrosarcoma. A comparative study of cellular DNA content and clinicopathologic features. Cancer 1982;50:577–583.
Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC: Chondrosarcoma of bone: An assessment of outcome. J Bone Joint Surg 1999;81-A:326–338.
Scully SP, Layfield LJ, Harrelson JM: Prognostic markers in chondrosarcoma: Evaluation of cell proliferation and regulators of the cell cycle. Sarcoma 1997;1:79–87.
- Tremble P, Chiquet-Ehrismann R, Werb Z: The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994;5:439–453.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.